Quoi de neuf dans les spondyloarthrites ?
-
Published:2023-03
Issue:2
Volume:90
Page:2S9-2S12
-
ISSN:1169-8330
-
Container-title:Revue du Rhumatisme
-
language:fr
-
Short-container-title:Revue du Rhumatisme
Reference10 articles.
1. 0P0255 Bimekizumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: 16-Week Efficacy & Safety from BE COMPLETE, a Phase 3, Multicentre Randomized Placebo-Ccontrolled Study;Merola;Ann Rheum Dis,2022
2. Bimekizumab in Patients with Active Psoriatic Arthritis, Naive to Biologic Treatment: a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (BE OPTIMAL);McInnes;Lancet,2023
3. Bimekizumab in Patients with Active Psoriatic Arthritis: Results from a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial;Ritchlin;Lancet,2020
4. Health Related Utility Measurement in Rheumatology: an Introduction;Bakker;Patient Educ Couns,1993
5. Normative Values for the Health Assessment Questionnaire Disability Index: Benchmarking Disability in the General Population;Krishnan;Arthritis Rheum,2004